Therapeutic efficacy of melatonin in reducing retinal damage in an experimental model of early type 2 diabetes in rats

Journal of Pineal Research

Volumn 54, Issue 2, 2013, Pages 179-189

  Salido, Ezequiel M ^a   Bordone, Melina ^a   De Laurentiis, Andrea ^a   Chianelli, Mõnica ^a   Keller Sarmiento, María Inés ^a   Dorfman, Damián ^a   Rosenstein, Ruth E ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

diabetic retinopathy; experimental type 2 diabetes mellitus; melatonin

Indexed keywords

CATALASE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE; MELATONIN; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

A WAVE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B WAVE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIET RESTRICTION; DRUG EFFICACY; ENZYME ACTIVITY; EXPERIMENTAL MODEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; INSULIN TOLERANCE TEST; LIPID PEROXIDATION; MALE; MUELLER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSCILLATORY POTENTIAL; RAT; STREPTOZOCIN DIABETES;

ANIMALS; CATALASE; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; GLUCOSE; IMMUNOHISTOCHEMISTRY; MALE; MELATONIN; RATS; RATS, WISTAR; THIOBARBITURATES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873464278     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12008     Document Type: Article

References (50)

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011; 378: 31-40.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008; 31: S55-S60.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
4. Movassat J, Saulnier C, Portha B,. Beta-cell mass depletion precedes the onset of hyperglycemia in the GK rat, a genetic model of non-insulindependent diabetes mellitus. Diabetes Metab 1995; 21: 365-370.
5. Matsuura T, Yamagishi S, Kodama Y, Shibata R, Ueda S, Narama I,. Otsuka Long-Evan Tokushima Fatty (OLETF) rat is not a suitable animal model for the study of angiopathic diabetic retinopathy. Int J Tissue React 2005; 27: 59-62.
6. Portha B, Blondel O, Serradas P, et al. The rat models of non-insulin dependent diabetes induced by neonatal streptozotocin. Diabetes Metab 1989; 15: 61-75.
7. Bray GA,. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583-2589.
8. Goralski KB, Sinal CJ,. Type 2 diabetes and cardiovascular disease: getting to the fat of the matter. Can J Physiol Pharmacol 2007; 85: 113-132.
9. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN,. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 1988; 37: 1163-1167.
10. Mühlhausler BS,. Nutritional models of type 2 diabetes mellitus. Methods Mol Biol 2009; 560: 19-36.
11. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
12. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP. UKPDS 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
13. Stolar M,. Glycemic control and complications in type 2 diabetes mellitus. Am J Med 2010; 123: S3-S11.
14. Salido EM, De Zavalía N, Schreier L, et al. Retinal changes in an experimental model of early type 2 diabetes in rats characterized by non-fasting hyperglycemia. Exp Neurol 2012; 236: 151-160.
15. Kowluru RA, Chan PS,. Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007; 2007: 43603.
16. Zheng L, Kern TS,. Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy. Front Biosci 2009; 14: 3974-3987.
17. Tang J, Kern TS,. Inflammation in diabetic retinopathy. Prog Retin Eye Res 2011; 30: 343-358.
18. Galano A, Tan DX, Reiter RJ,. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
19. Baydas G, Tuzcu M, Yasar A, Baydas B,. Early changes in glial reactivity and lipid peroxidation in diabetic rat retina: effects of melatonin. Acta Diabetol 2004; 41: 123-128.
20. Bonnefont-Rousselot D, Collin F, Jore D, Gardès-Albert M,. Reaction mechanism of melatonin oxidation by reactive oxygen species in vitro. J Pineal Res 2011; 50: 328-335.
21. Hardeland R, Tan DX, Reiter RJ,. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009; 47: 109-126.
22. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36: 1-9.
23. Sáenz DA, Turjanski AG, Sacca GB, et al. Physiological concentrations of melatonin inhibit the nitridergic pathway in the Syrian hamster retina. J Pineal Res 2002; 33: 31-36.
24. Gül M, Emre S, Eşrefoǧlu M, Vard N,. Protective effects of melatonin and aminoguanidine on the cornea in streptozotocin-induced diabetic rats. Cornea 2008; 27: 795-801.
25. Colantuoni A, Longoni B, Marchiafava PL,. Retinal photoreceptors of Syrian hamsters undergo oxidative stress during streptozotocin-induced diabetes. Diabetologia 2002; 45: 121-124.
26. Gürpinar T, Ekerbiçer N, Uysal N, Barut T, Tarakçi F, Tuglu MI., The effects of the melatonin treatment on the oxidative stress and apoptosis in diabetic eye and brain. Sci World J 2012; 2012: 498489-498493.
27. Fernandez DC, Chianelli MS, Rosenstein RE,. Involvement of glutamate in retinal protection against ischemia/reperfusion damage induced by post-conditioning. J Neurochem 2009; 111: 488-498.
28. Belforte NA, Moreno MC, De Zavalía N, et al. Melatonin: a novel neuroprotectant for the treatment of glaucoma. J Pineal Res 2010; 48: 353-364.
29. Moreno MC, Campanelli J, Sande P, Sáenz DA, Keller Sarmiento MI, Rosenstein RE,. Retinal oxidative stress induced by high intraocular pressure. Free Radic Biol Med 2004; 37: 803-812.
30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ,. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
31. Agil A, Rosado I, Ruiz R, Figueroa A, Zen N, Fernández- Vázquez G,. Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats. J Pineal Res 2012; 52: 203-210.
32. Shieh JM, Wu HT, Cheng KC, Cheng JT,. Melatonin ameliorates high fat diet-induced diabetes and stimulates glycogen synthesis via a PKCzeta-Akt-GSK3beta pathway in hepatic cells. J Pineal Res 2009; 47: 339-344.
33. Nishida S, Segawa T, Murai I, Nakagawa S,. Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Delta-5 desaturase activity. J Pineal Res 2002; 32: 26-33.
34. Hussain SA, Khadim HM, Khalaf BH, Ismail SH, Hussein KI, Sahib AS,. Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin. Saudi Med J 2006; 27: 1483-1488.
35. Peschke E, Schucht H, Mühlbauer E,. Long-term enteral administration of melatonin reduces plasma insulin and increases expression of pineal insulin receptors in both Wistar and type 2-diabetic Goto-Kakizaki rats. J Pineal Res 2010; 49: 373-381.
36. Sudnikovich EJ, Maksimchik YZ, Zabrodskaya SV, et al. Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats. Eur J Pharmacol 2007; 569: 180-187.
37. Guven A, Yavuz O, Cam M, Comunoglu C, Sevi'nc O,. Central nervous system complications of diabetes in streptozotocin-induced diabetic rats: a histopathological and immunohistochemical examination. Int J Neurosci 2009; 119: 1155-1169.
38. Tzekov R, Arden GB,. The electroretinogram in diabetic retinopathy. Surv Ophthalmol 1999; 44: 53-60.
39. Cunha-Vaz J, Bernardes R,. Nonproliferative retinopathy in diabetes type 2. Initial stages and characterization of phenotypes. Prog Retin Eye Res 2005; 24: 355-377.
40. Hammes HP, Federoff HJ, Brownlee M,. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med 1995; 1: 527-534.
41. Lutty GA, McLeod DS, Merges C, Diggs A, Plouét J,. Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol 1996; 114: 971-977.
42. Aiello LP, Wong JS,. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int 2000; 77: S113-S119.
43. Nicholson BP, Schachat AP,. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248: 915-930.
44. Mokini Z, Marcovecchio ML, Chiarelli F,. Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular pathways. Diabetes Res Clin Pract 2010; 87: 313-321.
45. Zavodnik IB, Lapshina EA, Cheshchevik VT, et al. Melatonin and succinate reduce rat liver mitochondrial dysfunction in diabetes. J Physiol Pharmacol 2011; 62: 421-427.
46. Kaul K, Hodgkinson A, Tarr JM, Kohner EM, Chibber R,. Is inflammation a common retinal-renal-nerve pathogenic link in diabetes? Curr Diabetes Rev 2010; 6: 294-303.
47. Negi G, Kumar A, Sharma SS,. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-κB and Nrf2 cascades. J Pineal Res 2011; 50: 124-131.
48. Korkmaz A, Ma S, Topal T, Rosales-Corral S, Tan DX, Reiter RJ,. Glucose: a vital toxin and potential utility of melatonin in protecting against the diabetic state. Mol Cell Endocrinol 2012; 349: 128-137.
49. Jahnke G, Marr M, Myers C, Wilson R, Travlos G, Price C,. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci 1999; 50: 271-279.
50. Jan JE, Hamilton D, Seward N, Fast DK, Freeman RD, Laudon M,. Clinical trials of controlled-release melatonin in children with sleep-wake cycle disorders. J Pineal Res 2000; 29: 34-39.